Phase II Clinical Study on the Efficacy and Safety of Immune Checkpoint Inhibitor Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory and Metastatic Colorectal Cancer
Latest Information Update: 30 Mar 2023
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary) ; Tislelizumab (Primary)
- Indications Colon cancer; Colorectal cancer
- Focus Therapeutic Use
- 27 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium
- 07 Jun 2022 Results (n=35) presented at the 58th Annual Meeting of the American Society of Clinical Oncology.